Literature DB >> 23453973

Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1-7) action on these pathways in cultured human myotubes.

Marta Montori-Grau1, Núria Tarrats, Oscar Osorio-Conles, Anna Orozco, Lucía Serrano-Marco, Manuel Vázquez-Carrera, Anna M Gómez-Foix.   

Abstract

Glycogen synthase (GS) is activated by glucose/glycogen depletion in skeletal muscle cells, but the contributing signaling pathways, including the chief GS regulator GSK3, have not been fully defined. The MEK/ERK pathway is known to regulate GSK3 and respond to glucose. The aim of this study was to elucidate the GSK3 and MEK/ERK pathway contribution to GS activation by glucose deprivation in cultured human myotubes. Moreover, we tested the glucose-dependence of GSK3 and MEK/ERK effects on GS and angiotensin (1-7) actions on these pathways. We show that glucose deprivation activated GS, but did not change phospho-GS (Ser640/1), GSK3β activity or activity-activating phosphorylation of ERK1/2. We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively. SB415286 activated GS and decreased the relative phospho-GS (Ser640/1) level, more in glucose-depleted than -replete cells. U0126 activated GS and reduced the phospho-GS (Ser640/1) content significantly in glucose-depleted cells, while GSK3β activity tended to increase. LY294 inactivated GS in glucose-depleted cells only, without affecting relative phospho-GS (Ser640/1) level. Rapamycin had no effect on GS activation. Angiotensin-(1-7) raised phospho-ERK1/2 but not phospho-GSK3β (Ser9) content, while it inactivated GS and increased GS phosphorylation on Ser640/1, in glucose-replete cells. In glucose-depleted cells, angiotensin-(1-7) effects on ERK1/2 and GS were reverted, while relative phospho-GSK3β (Ser9) content decreased. In conclusion, activation of GS by glucose deprivation is not due to GS Ser640/1 dephosphorylation, GSK3β or ERK1/2 regulation in cultured myotubes. However, glucose depletion enhances GS activation/Ser640/1 dephosphorylation due to both GSK3 and MEK/ERK inhibition. Angiotensin-(1-7) inactivates GS in glucose-replete cells in association with ERK1/2 activation, not with GSK3 regulation, and glucose deprivation reverts both hormone effects. Thus, the ERK1/2 pathway negatively regulates GS activity in myotubes, without involving GSK3 regulation, and as a function of the presence of glucose.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453973     DOI: 10.1016/j.cellsig.2013.02.014

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  miR-217-casein kinase-2 cross talk regulates ERK activation in ganglioglioma.

Authors:  Atreye Majumdar; Fahim Ahmad; Touseef Sheikh; Reshma Bhagat; Pankaj Pathak; Shanker Datt Joshi; Pankaj Seth; Vivek Tandon; Manjari Tripathi; P Saratchandra; Chitra Sarkar; Ellora Sen
Journal:  J Mol Med (Berl)       Date:  2017-08-25       Impact factor: 4.599

2.  Hypoglycaemic effects of glimepiride in sulfonylurea receptor 1 deficient rat.

Authors:  Xiaojun Zhou; Rui Zhang; Zhiwei Zou; Xue Shen; Tianyue Xie; Chunmei Xu; Jianjun Dong; Lin Liao
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

Review 3.  Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.

Authors:  Mahdi Rizk; Zahraa Saker; Hisham F Bahmad; Sanaa Nabha; Hayat Harati; Youssef Fares
Journal:  Mol Biol Rep       Date:  2021-03-01       Impact factor: 2.316

4.  Transcriptional regulation of pig GYS1 gene by glycogen synthase kinase 3β (GSK3β).

Authors:  Yilin Wang; Yan Wang; Tao Zhong; Jiazhong Guo; Li Li; Hongping Zhang; Linjie Wang
Journal:  Mol Cell Biochem       Date:  2016-10-26       Impact factor: 3.396

5.  Antioxidative and Hypoglycemic Effect of Ta-ermi Extracts on Streptozotocin-Induced Diabetes.

Authors:  Siqun Jing; Zhengmei Zhao; Jinzi Wu; Liang-Jun Yan
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-23       Impact factor: 3.168

Review 6.  Muscle wasting: A review of exercise, classical and non-classical RAS axes.

Authors:  Mark A Winslow; Stephanie E Hall
Journal:  J Cell Mol Med       Date:  2019-07-05       Impact factor: 5.310

Review 7.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Authors:  Mukesh K Pandey; Timothy R DeGrado
Journal:  Theranostics       Date:  2016-02-17       Impact factor: 11.556

Review 8.  Impact of Conventional and Atypical MAPKs on the Development of Metabolic Diseases.

Authors:  Toufic Kassouf; Grzegorz Sumara
Journal:  Biomolecules       Date:  2020-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.